Active Surveillance for Localized Prostate Cancer (eBook)

Chapter 1. The Problem of Cancer Overdiagnosis and Overtreatmentby Laurence KlotzChapter 2. Patient Selection for Active Surveillanceby John Eifler and H. Ballentine CarterChapter 3. Predicting High Risk Disease Using Tissue Biomarkersby Michael J. Donovan and Carlos Cordon-CardoChapter 4. Predicting High Risk Disease Using Serum and DNA Biomarkersby Danny Vesprini and Robert NamChapter 5. Triggers for Intervention in Men on Surveillanceby S.Y. Jackie Sham and Chris ParkerChapter 6. The Role of MRI in Active Surveillance by Caroline M. Moore, Clare Allen, Mark EmbertonChapter 7. Active Surveillance:  The European Experienceby Meelan Bul, Monique J. Roobol and Chris H. Bangma Chapter 8. Active Surveillance:  The Canadian Experienceby Laurence KlotzChapter 9. Psychosocial Aspects of Active Surveillanceby Meredith Wallace Kazer, Dwanna M. Ward-Boahen, David M. Latini, Donald E. Bailey, Jr.Chapter 10. Statistical Considerations for Patient Selection and Triggers for Intervention in Active Surveillanceby Andrew J. VickersChapter 11. Interpreting PSA Kinetics using GLMM Techniqueby Liying Zhang and Laurence KlotzChapter 12. The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancerby Stacey A. Kenfield, J. Kellogg Parsons, June M. ChanChapter 13. The Role of 5α-Reductase Inhibitors (5-ARIs) in Expectant Management of Low Risk Prostate Cancer by David Margel and Neil FleshnerChapter 14. Urologists’ Opinion on Active Surveillance: United States vs. the Netherlands by Lionne D.F. Venderbos, Chris H. Bangma, Ida J. Korfage Chapter 15. Clinical ‘Pearls’ in Managing Patients on Surveillanceby Laurence KlotzChapter 16. Active Surveillance, Focal Therapy and the Futureby Mark EmbertonChapter 17. The Economics of Active Surveillance for Prostate Cancerby Marc A. Dall’Era and Christopher P. EvansChapter 18. The Future of Active Surveillanceby Sima P. Porten, Jared M. Whitson, Peter R. Carroll